Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adal

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 7/8/2026

1. USO
2. SPY
3. TMUS
4. KRUS
5. MTZ
6. AMZN
7. RKLB
8. FLUT
9. PENG
10. KLAR

Go back to Additional results from pivotal RA-BEAM study published in New England Journal of Medicine show baricitinib-treated patients demonstrated sustained improvement in rheumatoid arthritis compared to adal

Jefferies Reiterates Buy Rating and $140 PT on Incyte Corp. (INCY); EU Bari Label In-Line

February 17, 2017 8:37 AM EST

Jefferies analyst Brian Abrahams reiterates Buy rating and $140 price target on Incyte Corp. (NASDAQ: INCY), noting no major updates with EUs Olumiant/bari label, removing potential risks to near term US approval.

Abrahams writes, "EUs Olumiant/bari label contains no major surprises vs.... More